ceftazidime-avibactam offers a differentiated profile versus existing treatment options in serious Gram-negative infections through its coverage of a broad range of species of carbapenem-resistant Enterobacteriaceae (CRE) together with difficult to treat Pseudomonas aeruginosa combined with robust coverage of extended spectrum B-lactamase
Rapid dissemination and diversity of CTX-M extended-spectrum b-lactamase
genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America.
Phenotypic detection of carbapenem susceptible metallo B-lactamase
producing Gram negative bacilli in the clinical laboratory.
(ESBL) Producing Enterobacteriaeciae from the UK
These data confirm the presence of an extended spectrum b-lactamase
(ESBL) producing IncHI2 plasmid in strain A54560 that is capable of con jugative transfer and suggest that the plasmid might have been acquired by residual index strain within the patient by transfer from an unknown donor bacterium.
Group 6 - Antibacterials B-lactam penicillin susceptible to B-lactamase
See "P1A Recombinant B-Lactamase
Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin", Antimicrobial Agents and Chemotherapy 2009; 53: 2455-2462
Highlights to include: -- Avidia uses avimers to create inhibitors to block IL-6 -- Compound Therapeutics developed AdNectin as an agonist to VEGFR-2 -- Molecular Partners AG developed DARPins for diagnostic and therapeutic applications -- Dyax engineered Kunitz domain-based drug candidates that are in clinical and preclinical testing -- Genecor constructed fusion proteins between fragments of tumor specific antibodies and B-lactamase
Keynote Addresses: Fundamentals and Applications for Engineering Proteolytic Activity
BP-102/Tazobactam, a parenteral, bactericidal fixed combination of a proprietary broad-spectrum carbacephem compound and a well-established b-lactamase
inhibitor, now in late-stage preclinical development.